Cutaneous Lupus Erythematosus Research Trial (20 Weeks)

Inclusion criteria :

Participants with cutaneous lupus erythematosus either in the form of discoid/chronic cutaneous lupus erythematosus or subacute cutaneous lupus erythematosus for at least 3 months before Screening.
Participants with histologically confirmed and documented diagnosis within one year prior to Screening or during Screening period prior to randomization.
Active cutaneous lupus erythematosus skin lesions and a Cutaneous Erythematosus.
Disease Area and Severity Index activity (CLASI-A) ≥10 both at Screening and Baseline.
Participant who is candidate for systemic treatment per Investigator’s judgement.

Exclusion criteria:

Systemic lupus erythematosus according to the 2012 SLICC criteria with major organ involvement.
Suspected or proven drug induced lupus erythematosus, including patients with positive antihistone autoantibody tests.
Autoimmune disease(s) other than systemic lupus erythematosus.
Active skin diseases that may interfere with the study or study assessments.
Exclusion related to tuberculosis, non-tuberculous mycobacterial infections, HIV, HBV, HCV, Herpes zoster, COVID-19 and other recurrent or recent serious infections.
Prolonged QTcF ≥ 450 ms (by Fridericia formula) or clinically significant findings on electrocardiogram (ECG).
Cannot avoid excessive UV exposure 4 weeks prior to baseline and during the study. Routine sun exposure through work are permitted but requires the use of sun block to sun exposed areas for at least 4 weeks prior to baseline and during the study.
Concomitant treatment with topical immunosuppressants beyond a stable regimen of low to medium potency topical corticosteroids and/or topical calcineurin inhibitors during the study and two weeks before baseline visit.
Initiation and/or changes in dosage of chloroquine/hydroxychloroquine within 12 weeks prior to Screening visit (or during Screening period) and/or the dose exceeding 2.3 mg/kg/day for chloroquine or 400 mg/day for hydroxychloroquine.
Systemic treatments for cutaneous or systemic lupus erythematosus or immunosuppressive therapy for autoimmune disease other than the study medication.
Systemic corticosteroids treatment <4 weeks before baseline visit.
Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study.
Laboratory abnormalities at the Screening visit.

The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.